The Pharmaceutical Journal
Vol 271 No 7270 p488
11 October 2003

This article
Reprint
Photocopy

R & D News summary

Related websites
European College of Neuropsychopharmacology congress (www.ecnp.nl)

Anxiety now target for new drug

Aprepitant, the substance P receptor antagonist approved by the United States Food and Drug Administration in March 2003 for treating chemotherapy induced nausea and vomiting, is in phase III trials as a treatment for anxiety.

The Journal attended the European College of Neuropsychopharmacology congress courtesy of Eli Lilly